Literature DB >> 31833540

Piperacillin-Tazobactam Added to Vancomycin Increases Risk for Acute Kidney Injury: Fact or Fiction?

Sean N Avedissian1,2, Gwendolyn M Pais3,4, Jiajun Liu3,4, Nathaniel J Rhodes3,4, Marc H Scheetz3,4.   

Abstract

Vancomycin and piperacillin-tazobactam are 2 of the most commonly prescribed antibiotics in hospitals. Recent data from multiple meta-analyses suggest that the combination increases the risk for vancomycin-induced kidney injury when compared to alternative viable options. However, these studies are unable to prove biologic plausibility and causality as randomized controlled trials have not been performed. Furthermore, these studies define acute kidney injury according to thresholds of serum creatinine rise. Serum creatinine is not a direct indicator of renal injury, rather a surrogate of glomerular function. More reliable, specific, and sensitive biomarkers are needed to truly define if there is a causal relationship with increased toxicity when piperacillin-tazobactam is added to vancomycin. This viewpoint will explore the available evidence for and against increased acute kidney injury in the setting of vancomycin and piperacillin-tazobactam coadministration.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Bradford Hill criteria; acute kidney injury; piperacillin-tazobactam; vancomycin

Year:  2020        PMID: 31833540     DOI: 10.1093/cid/ciz1189

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  6 in total

1.  Risk Factors for Nephrotoxicity in Methicillin-Resistant Staphylococcus aureus Bacteraemia: A Post Hoc Analysis of the CAMERA2 Trial.

Authors:  Amy Legg; Niamh Meagher; Sandra A Johnson; Matthew A Roberts; Alan Cass; Marc H Scheetz; Jane Davies; Jason A Roberts; Joshua S Davis; Steven Y C Tong
Journal:  Clin Drug Investig       Date:  2022-10-10       Impact factor: 3.580

2.  Glomerular Function and Urinary Biomarker Changes between Vancomycin and Vancomycin plus Piperacillin-Tazobactam in a Translational Rat Model.

Authors:  Jack Chang; Gwendolyn M Pais; Kimberly Valdez; Sylwia Marianski; Erin F Barreto; Marc H Scheetz
Journal:  Antimicrob Agents Chemother       Date:  2022-01-10       Impact factor: 5.938

Review 3.  Vancomycin-Associated Acute Kidney Injury: A Narrative Review from Pathophysiology to Clinical Application.

Authors:  Wei-Chih Kan; Yi-Chih Chen; Vin-Cent Wu; Chih-Chung Shiao
Journal:  Int J Mol Sci       Date:  2022-02-12       Impact factor: 5.923

Review 4.  β-Lactam Therapeutic Drug Monitoring in Critically Ill Patients: Weighing the Challenges and Opportunities to Assess Clinical Value.

Authors:  Thomas J Dilworth; Lucas T Schulz; Scott T Micek; Marin H Kollef; Warren E Rose
Journal:  Crit Care Explor       Date:  2022-07-05

Review 5.  Piperacillin-Tazobactam Plus Vancomycin-Associated Acute Kidney Injury in Adults: Can Teicoplanin or Other Antipseudomonal Beta-Lactams Be Remedies?

Authors:  Abdullah Tarık Aslan; Murat Akova
Journal:  Healthcare (Basel)       Date:  2022-08-20

6.  Association of vancomycin plus piperacillin-tazobactam with early changes in creatinine versus cystatin C in critically ill adults: a prospective cohort study.

Authors:  Nuala J Meyer; Michael G S Shashaty; Todd A Miano; Sean Hennessy; Wei Yang; Thomas G Dunn; Ariel R Weisman; Oluwatosin Oniyide; Roseline S Agyekum; Alexandra P Turner; Caroline A G Ittner; Brian J Anderson; F Perry Wilson; Raymond Townsend; John P Reilly; Heather M Giannini; Christopher V Cosgriff; Tiffanie K Jones
Journal:  Intensive Care Med       Date:  2022-07-14       Impact factor: 41.787

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.